Dabur's healthcare portfolio may provide the much-needed boost in FY24
Performance of the healthcare division in FY23 was relatively weak, with a 7% revenue drop. However, restructuring efforts are projected to yield a high-single to low double-digit growth rate in FY24, under the leadership of former Himalaya Drug Company chief executive, Philipe Haydon.29-06-2023